Bioavailability of Belumosudil (KD025) in Healthy Male Subjects

Phase 1 Completed 23 enrolled Kadmon Corporation, LLC Quotient Clinical · collab

RandomizedCrossoverOpen-labelOther

Summary

Phase 1 bioavailability study to evaluate the pharmacokinetics (PK) and tolerability/safety of the belumosudil tablet formulation in the fasted and fed states and compared to the belumosudil capsule formulation in the fed state.

Timeline

Start: 2015-09
Primary completion: 2015-10-12
Completion: 2015-10-12

Publications

Background Schueller O, McDermott J, Evans P, Lohmer L, Alabanza A, Patel J. Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects. Clin Pharmacol Drug Dev. 2022 Jul;11(7):807-814. doi: 10.1002/cpdd.1083. Epub 2022 Mar 2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Belumosudil	Small molecule	200 mg	—

Indications

No indication recorded.